The outcome of patients with unresectable or metastatic soft tissue sarcoma (STS) remains poor with few treatment options. A number of randomized trials in the first-line setting have shown no difference in overall survival between combination anthracycline schedules and single-agent doxorubicin. A Phase Ib/randomized Phase II trial of doxorubicin with or without the platelet-derived growth factor receptor-α (PDGFRα)-blocking antibody, olaratumab, demonstrated a significant difference in median overall survival in favor of the olaratumab arm. The results of this trial led to the approval of olaratumab in combination with doxorubicin in adult anthracycline-naïve unresectable STS. In this review, we discuss the potential role of PDGFRα signaling, early clinical data with olaratumab in sarcomas, the Phase Ib/II trial and ongoing trials with olaratumab in sarcomas.
Introduction
Therapeutic options for advanced and metastatic soft tissue sarcomas (STSs) are limited, and median overall survival (OS) is approximately 18 months. The role of doxorubicin as first-line therapy in adult advanced STS is well established. [1] [2] [3] The addition of other agents in combination with doxorubicin has yet to show an additional survival benefit despite encouraging Phase II results, including newer agents such as palifosfamide 3 and evofosfamide. 4 Notably, the randomized Phase III trials of both palifosfamide and evofosfamide showed no significant difference in progression-free survival (PFS) or OS as compared with doxorubicin monotherapy. Alternative drug combinations such as gemcitabine and docetaxel have also not shown a PFS or OS benefit. 
Platelet-derived growth factor receptor (PDGFR) signaling in cancer
The potential importance of targeting PDGFR signaling in cancer paved the way for the development of olaratumab. PDGFR tyrosine kinases are overexpressed in a number of tumor types, [6] [7] [8] [9] including sarcomas, prostate, breast, ovarian and lung cancer. 10, 11 Inhibition of the platelet-derived growth factor receptor-α (PDGFRα) signaling pathway limits tumor growth and metastasis in vitro and in animal models. 12, 13 Amplification of the genomic region encoding PDGFRα in non-small-cell lung cancer (NSCLC) corresponds to overexpression of PDGFRα in vitro, and the activity of this pathway drives cell growth. 7 Similarly, the overexpression of PDGF isoforms in mice leads to glioma development.
14 PDGF isoforms (PDGF-AA, PDGF-AB and PDGF-BB) have a role in chemokine signaling to the tumor microenvironment and stimulating stromal cells ( Figure 1 ). 15 PDGFRα expression in breast cancer is associated with more aggressive and HER2-positive and node-positive disease. 6 A high level of both PDGFRα and PDGF-A within these tumors supports a possible autocrine mechanism for the role of PDGFR signaling in tumor cell growth. PDGF signaling has also been linked with TGF-β signaling and epithelial-mesenchymal transition, a key step in tumor metastasis, in prostate, pancreatic and hepatocellular carcinomas. 16 
Early development of olaratumab
To inhibit binding of various PDGF ligands and activation of PDGFRα, a fully human IgGl monoclonal antibody (mAb) was developed. Olaratumab (IMC-3G3) prevents PDGF-AA and PDGF-BB binding, thus reducing receptor autophosphorylation to background levels, 17 and selectively inhibits downstream PDGFRα signaling in vitro. The high affinity of the antibody for PDGFRα (40 pM) potentially avoids side effects secondary to multi-kinase receptor inhibition. 18, 19 SK-LMS-1, a leiomyosarcoma cell line, responds to PDGF stimulation. 17 PDGF-AA is expressed in the culture medium when the cells are grown in vitro, supporting an autocrine role for PDGF signaling in these cells. Olaratumab has antitumor activity against a xenograft model of SK-LMS-1 in nude mice at doses between 6 and 20 mg/kg twice weekly. Tumor volumes are between 35% and 67% smaller with olaratumab treatment than in mice treated with control human IgG. 17 Tumor cell and stromal cell PDGFRα expression can influence response to drugs affecting PDGFR signaling. Mice xenografts of PDGFRα-expressing and PDGFRα-negative human lung cancer cell lines were treated with the antihuman olaratumab, and IE10, an anti-mouse PDGFRα mAb. Olaratumab inhibited the growth of PDGFRα-expressing xenografts. Xenografts with low levels of tumor PDGFRα expression and high levels of PDGF-AA expression were inhibited by 1E10 targeting the mouse stromal cells. Thus, PDGF signaling in the stroma may influence the response to anti-PDGF therapeutics as much as tumor PDGF signaling. 20 Targeting the mouse stromal cells in an animal model of prostate cancer did not slow down or prevent the development of skeletal metastases however, whereas olaratumab treatment prevented bone colonization and reduced skeletal disease burden.
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Phase I olaratumab data A 19-patient Phase I dose-escalation trial evaluated singleagent olaratumab using five different doses and schedule cohorts: 4, 8 or 16 mg/kg weekly or 15 or 20 mg/kg twoweekly. 22 The rationale for these doses and schedules was based on observed tumor growth inhibition in U118 glioblastoma and SK-LMS-1 leiomyosarcoma xenograft models at a measured trough concentration of 155-210 μg/mL. 17 Patients in the weekly cohorts were evaluated after four treatments and 2 weeks of observation (at 6 weeks), and those receiving two-weekly treatments were evaluated after four treatments (8 weeks) . No dose-limiting toxicities were recorded and so no maximum tolerated dose reached.
The majority of patients enrolled in the study had metastatic prostate cancer (11/19, 57 .9%), and no sarcoma patients were enrolled. Eight out of 19 patients (42.1%) experienced olaratumab-related adverse events, most commonly infusion reactions and fatigue. Two episodes of grade 3 elevated alkaline phosphatase were attributed to olaratumab. Two serious adverse events (grade 2 tumor hemorrhage and grade 2 elevated alkaline phosphatase) were noted as possibly drug related.
The median duration of response was 3.9 weeks (95% CI 2.3-8.7 months), and the best response to treatment was 
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Olaratumab for the treatment of soft tissue sarcoma stable disease. Four (21%) patients had more than 6 months (range 8.5-13.1 months) of disease stabilization on treatment across a range of dose schedules (4 and 16 mg/kg weekly and 15 and 20 mg/kg two-weekly). Pharmocokinetics showed that the 16 mg/kg weekly and 20 mg/kg two-weekly schedules resulted in steady state serum trough olaratumab concentrations that were greater than 155 μg/mL, the plasma concentration that was effective in xenograft studies, and consequently, these are the recommended dose schedules based on this study.
Olaratumab in sarcomas: Phase Ib/II trial
The promising activity of olaratumab with doxorubicin in a Phase Ib/II open-label clinical trial 23 has fueled enthusiasm to take this compound into later-stage clinical trial development. Xenograft models suggest synergism with doxorubicin chemotherapy for up to eight cycles of treatment (unpublished data). In the Phase Ib/II study, olaratumab was given at 15 mg/ kg on day 1 and day 8 of a three-weekly schedule alongside 75 mg/m 2 doxorubicin on day 1 every 21 days. 23 Dexrazoxane was given alongside cycles 5-8 of doxorubicin to reduce the risk of anthracycline cardiotoxicity. 24 The Phase Ib component of the study recruited 15 patients, and 133 patients were enrolled in the Phase II component. Sixty-six patients were randomized to doxorubicin and olaratumab, and 67 patients to doxorubicin alone in the Phase II study. The proportion of patients with leiomyosarcoma was balanced between the two arms (36.4% [24/66] doxorubicin and olaratumab vs. 40.3% [27/67] doxorubicin). The Phase II trial analysis was stratified for histological subtype: leiomyosarcoma, synovial sarcoma and "other" subtypes. Inevitably, as with all trials in STSs, the "other" cohort consisted of a heterogeneous group of subtypes in both arms.
The primary end point of the Phase II study was designed to detect a 50% improvement in median PFS in the olaratumab and doxorubicin group. This analysis was performed based on investigator assessment of 103 events. Due to the inherent bias of an open-label study, the imaging analysis was retrospectively reviewed in a blinded fashion. The median PFS for olaratumab using investigator assessment was 6.6 months (95% CI 4.1-8.3) and retrospective review was 8.2 months (95% CI 5.5-9.8) as compared with 4.1 months (95% CI 2.8-5.4) and 4.4 months (95% CI 3.1-7.4), respectively, for doxorubicin alone. To meet the planned criteria for significance, the combination arm would need to extend the PFS interval by approximately 8 weeks, an incremental but potentially meaningful improvement in a patient group, where greater than 50% had already received one prior line of systemic therapy for local or advanced disease.
Despite the modest increase in PFS with doxorubicin and olaratumab, there was a significant OS benefit observed in the study: 14.7 months (95% CI 9.2-17.1 months) with doxorubicin alone compared to 26.5 months with the combination (95% CI 20.9-31.7 months, hazard ratio [HR] 0.46, p=0.0003). The median exposure of patients in the combination arm to olaratumab was 26.1 weeks (range 3-128 weeks) which extends slightly beyond the time interval required to complete eight sequential doxorubicin treatments three weekly. This may reflect that PDGFRα inhibition affects the tumor microenvironment as much as the tumor cells, and so treatment effects have an impact which continues after cessation of treatment. 25 Another possibility is through an immune-mediated mechanism that delays the development of further metastatic disease. A discrepancy between PFS and OS has also been seen with a 452-patient study of eribulin vs. dacarbazine in lipo-and leiomyo-sarcomas, 26 with a PFS of 2.6 months observed in both groups but a median OS of 13.5 months (95% CI 10.9-15.6) and 11.5 months (95% CI 9.6-13.0), respectively. These data underline the importance of a preoperative biomarker trial with material-analyzed preand post-olaratumab exposure.
Thirty out of 67 (45%) patients in the doxorubicin-alone arm went on to receive olaratumab monotherapy post progression for a median of four infusions (6 weeks of treatment) as compared with 34/66 (52%) of patients in the combination arm who continued olaratumab post combination therapy for a median of nine infusions (13 weeks). This does not suggest a major role for single-agent olaratumab but supports a putative synergism between doxorubicin and olaratumab.
Mean steady state trough olaratumab levels (taken at the end of a cycle between cycles 4 and 9) were measured at 123-156 μg/mL, 23 which approximates to the effective trough level seen in xenograft models. 17 Interestingly, the patients with the highest quartile average and trough serum olaratumab levels, i.e., greatest exposure, showed a trend toward an improved PFS and OS. 23 An exploratory analysis of tumor PDGFRα expression did not reveal a significant relationship with PFS or OS; however, the assay was nonspecific and reanalysis of tumors with immunohistochemistry using a more specific antibody identified the expected proportion of detectable PDGFRα expression, which was well balanced between the two arms (33% patients receiving doxorubicin and olaratumab and 34% patients receiving doxorubicin). There was no relationship identified between PDGFRα expression and PFS or OS in this trial. 
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Pender and Jones Grade 3/4 adverse events occurred more frequently in the doxorubicin and olaratumab arm (38/42%) than the doxorubicinalone arm (38/31%), and doxorubicin-associated adverse events were more frequent in the combination arm including neutropenia, nausea and vomiting, diarrhea and mucositis. Thirteen percent of patients in the combination arm had infusion-related reactions. Despite a higher frequency of neutropenia in the doxorubicin and olaratumab group (58 vs. 35%), this did not result in more febrile neutropenia or hospital admissions. Treatment discontinuations due to toxicity and deaths were evenly balanced across both arms and nearly all attributable to progressive disease. This is, however, a relatively small patient population with routine use of growth factors on treatment and so larger studies with this combination may give further information about toxicity and mortality. Cardiac complications, excluding peripheral edema, were infrequent and occurred in 8% of patients treated with doxorubicin and olaratumab and 6% patients with doxorubicin alone.
In conclusion, this 148-patient Phase Ib/II study in adults with unresectable or metastatic STS reports that the addition of 15 mg/kg olaratumab on Days 1 and 8 of a 21-day cycle to doxorubicin 75 mg/m 2 3-weekly results in a significant improvement in median OS as compared with doxorubicin alone. The primary end point of the trial was a 50% improvement in PFS, and the end point was met although the difference in favor of the olaratumab arm was less impressive. This study has led to the Phase III placebo-controlled double-blind ANNOUNCE study of doxorubicin and olaratumab vs. doxorubicin and placebo in advanced or metastatic STS which is expected to report in 2020. In October 2016, the US Food and Drug Administration granted accelerated approval of olaratumab in combination with anthracycline-based chemotherapy in adults with non-curable STS. The European Medicines Agency echoed this decision in November 2016 with "conditional approval" of olaratumab with doxorubicin in the same patient population.
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Olaratumab in lung cancer: Phase II trial
A 131-patient Phase II trial randomized treatment-naïve adult patients with advanced NSCLC to carboplatin, paclitaxel and olaratumab treatment or carboplatin and paclitaxel treatment. 28 Olaratumab was given at 15 mg/kg on Days 1 and 8 alongside carboplatin AUC 6 and paclitaxel 200 mg/m 2 . Up to six cycles of chemotherapy were given and then the patients in the experimental arm received olaratumab maintenance therapy using the same schedule until progression. Patients in the control arm could cross over to the olaratumab arm on progression. There was no significant difference in PFS, OS or response rate between the two arms, and more neutropenia, thrombocytopenia and fatigue was reported in the experimental arm.
Olaratumab in gastrointestinal stromal tumors: Phase II trial
PDGFRa D842V mutations in gastrointestinal stromal tumors (GIST) confer resistance to imatinib, and this group of patients has poorer outcomes in the metastatic setting. 29 A small Phase II study evaluated the response to 20 mg/kg olaratumab every 14 days in adult patients with pretreatment metastatic GIST with and without a PDGFRa D842V mutation. 30 Seven patients with the D842V mutation received treatment as compared with 14 patients with PDGFRa wild-type (WT) tumors. The 12-week clinical benefit rate (defined as stable disease, partial or complete response) was 50.0% (15.3-84.7) in patients with mutant tumors and 14.3% (2.6-38.5) in PDGFRa WT tumors. Median PFS was 32.1 weeks (5.0-35.9) in PDGFRa D842V-mutant tumors as compared with 6.1 weeks (5.7-6.3) in PDGFRa WT tumors. Median OS is yet to be reached for the patients with PDGFRa D842V GIST and is 24.9 weeks (14.4-49.1 in patients without PDGFRa mutations. The most common toxicities were fatigue (38.1%), headache (19%), nausea (19%), peripheral edema (14.3%) and infusion reaction (14.3%). All patients who discontinued treatment within the study did so due to progressive disease. This limited study in a specific GIST population suggests some activity with olaratumab in PDGFRa D842V-mutant GIST, but further study is needed.
Olaratumab in sarcomas: ongoing trials
The Phase III double-blind placebo-controlled ANNOUNCE study of olaratumab and doxorubicin in patients with advanced or metastatic STS (NCT02451943) has completed 
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Olaratumab for the treatment of soft tissue sarcoma recruitment of 460 patients and analysis is awaited ( Table 1) . The first cycle of olaratumab was given at 20 mg/kg on Days 1 and 8 to ensure more rapid therapeutic serum olaratumab levels, given the data on drug exposure from the Phase II study. The two primary objectives of the study are the assessment of OS in all patients and in patients with leiomyosarcoma. Further work to develop our knowledge of the mechanism of olaratumab will be carried out in a Phase Ib study of 40 patients with potentially resectable STS who will receive olaratumab alone at 20 mg/kg on Day 1 and Day 8 of a three-weekly schedule for the first cycle and then 20 mg/kg olaratumab alongside 75 mg/m 2 doxorubicin on Day 1 every 21 days on cycle 2 (NCT02783599). From the third treatment cycle onward, patients will receive 15 mg/kg olaratumab on the same schedule alongside doxorubicin. Tissue samples will be taken pre and post olaratumab monotherapy with cycle 1, and tissue from later surgical resection will also be analyzed. The joint primary objectives of this study are to characterize circulating tumor cells pre and post olaratumab monotherapy and to analyze PDGFRα, PDGFRβ and PDGF ligand expression changes. The study will also provide further efficacy, safety and pharmacokinetic data.
Gemcitabine and docetaxel have shown similar activity to doxorubicin in advanced STS, 5 and there is a Phase Ib/II study of this combination with olaratumab in advanced or metastatic STS open for recruitment (NCT02659020). The primary objective of the Phase Ib part will be to recommend a Phase II dose of the triple combination. Both 15 and 20 mg/ kg olaratumab on Days 1 and 8 of a 21-day cycle will be evaluated, and 30 patients will be enrolled. The Phase II part of the study will aim to recruit 166 patients randomized 1:1 between gemcitabine, docetaxel and olaratumab vs. gemcitabine, docetaxel and placebo in a double-blinded fashion. The primary objective of the Phase II part of the trial is OS.
Another Phase I trial is evaluating the safety and tolerability of doxorubicin and ifosfamide in combination with olaratumab (NCT03283696). In addition, there is a Phase I trial of olaratumab in combination with pembrolizumab (NCT03126591) that is open for recruitment.
Conclusion
The outcome of adult patients with metastatic and locally advanced STS remains poor with a median OS of approximately 18 months. Previously, few systemic therapies have been available and largely limited to doxorubicin and ifosfamide. 2 Over the past decade, a number of effective agents have emerged to treat STS, including gemcitabine/docetaxel, 5 trabectedin, 31 pazopanib 32 and eribulin. 26 Despite extensive research, however, doxorubicin remains standard first-line therapy. The promising results of the randomized Phase II trial of olaratumab have led to rapid approval of this agent in Europe and the USA. Early studies have provided valuable information about the relationship between drug exposure and response. 19, 22, 23 The randomized Phase III trial will define the role of this agent, and ongoing trials will provide valuable data regarding the activity of this drug with other therapeutics and better define the mechanism of action. Future studies should evaluate the potential role of olaratumab in bone tumors such as osteosarcoma and Ewing sarcoma as well as investigate further combinations.
The randomized Phase III trial in sarcomas has completed enrollment, and it is hoped that it will lead to another treatment option for patients with these challenging and heterogeneous diseases.
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